Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-35
SponsorShanghai BDgene Co., Ltd.

About this trial

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Eligibility criteria

Qualifiers

The tumor genes chip detection results about acute leukemia and myeloid tumor gene mutations (panel) showed no abnormality.

There were candidates for HLA gene semi-compatible hematopoietic stem cell transplantation.

No eligiblity for allogeneic hematopoietic stem cell transplantation.

The treatment of erythrocyte maturation agent luspatercept cannot be financially supported.

Disqualifiers

Availability of voluntary, fully HLA-matched hematopoietic cell donors, unless recommended for inclusion by the Monitoring Committee.

HIV-1 and HIV-2 were positive, and / or HTLV-1, HTLV-2 and VSV-G antibodies were positive.

An active bacterial, viral, fungal or parasitic infection.

Contraindicated for the extraction of bone marrow under anesthesia.

Trial design

Treatments tested in this trial

  • BD211

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators

Shanghai BDgene Co., Ltd.

Lead sponsor

Ruijin Hospital

Collaborator